Compare Gilead Sciences, Inc. (GILD) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Iron Mountain Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Iron Mountain Inc trades at $114.51 (market cap $34.46B). The key difference: Gilead Sciences, Inc. is far larger — about 5.3× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Iron Mountain Inc for 80 Days on average.
| GILD | IRM | |
|---|---|---|
Market Cap | $182.40B | $34.46B |
Volume | 4,469,821 | 1,379,608 |
Sector | Health | Real Estate |
52-Week High | $155.80 | $133.06 |
52-Week Low | $117.18 | $78.86 |
Typical Hold Time | 111 Days | 80 Days |
Enterprise Value | $205.46B | $53.87B |
Dividend Yield | 2.23% | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Iron Mountain (IRM) trades at $112.97, down 2.38% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed from 10.91% to 2.09% over the same period. Recent news highlights expansion in data center capacity and digital partnerships, while institutional investors show mixed positioning with significant options activity.
The stock presents a growth story with data center expansion driving revenue, but faces headwinds from high debt levels (79.04% debt-to-asset ratio) and margin pressure. Analyst consensus remains bullish with a $142.75 price target representing 26% upside, though technical indicators suggest near-term caution. Key risks include interest rate sensitivity and execution challenges in digital transformation initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
